Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) saw a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 2,000 shares, a drop of 59.2% from the August 31st total of 4,900 shares. Based on an average trading volume of 470,000 shares, the days-to-cover ratio is presently 0.0 days.

Oncotelic Therapeutics Stock Performance

Oncotelic Therapeutics stock opened at $0.02 on Friday. Oncotelic Therapeutics has a one year low of $0.02 and a one year high of $0.05. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.01 and a quick ratio of 0.01. The business has a fifty day moving average of $0.02 and a two-hundred day moving average of $0.03.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.